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MINIREVIEW
FemABX Peptidyl Transferases: a Link between Branched-Chain Cell
Wall Peptide Formation and -Lactam Resistance
in Gram-Positive Cocci
S. Rohrer and B. Berger-Ba¨chi*
Institute of Medical Microbiology, University of Zu¨rich, CH-8028 Zu¨rich, Switzerland
Peptidoglycan biosynthesis is one of the preferred targets for
antibiotics, as peptidoglycan is unique to eubacteria and inhi-
bition of its production is generally bactericidal (Fig. 1). Pep-
tidoglycan, the major component of the bacterial cell wall,
forms the murein sacculus, a giant macromolecule that sur-
rounds the cell as a single, flexible meshwork and is intimately
involved in cell division. Its structure determines cell shape and
maintains cell integrity by protecting it against the high inter-
nal osmotic pressure. The most widely used class of antibiotics
that target the cell wall are -lactams and their derivatives.
Their introduction into therapy has, however, invariably been
followed by the development and spread of resistance in the
bacterial community. Gram-positive bacteria have developed two
main strategies against -lactams: drug inactivation by -lacta-
mases and intrinsic resistance mediated by modified, low-affin-
ity variants of the target enzymes, the so-called penicillin-binding
proteins (PBPs). To reach high-level -lactam resistance, the
low-affinity PBPs of staphylococci and pneumococci, in partic-
ular, depend on correctly synthesized peptidoglycan precur-
sors. Specifically, the interpeptide structure, which is charac-
teristic of the peptidoglycan of many gram-positive organisms
(Fig. 1; Table 1), has a great impact on the level of -lactam
resistance that is achieved, as will be discussed below.
Mechanism of -lactam action. -Lactams target the extra-
cellular steps of peptidoglycan biosynthesis by inhibiting the
PBPs that catalyze the transpeptidation reaction, the last step
in peptidoglycan synthesis (Fig. 1). Their localization at the
outer face of the cytoplasmic membrane makes PBPs a readily
accessible target. -Lactams accomplish inhibition of PBPs by
their structural similarity to the extended conformation of the
terminal D-Ala2 dipeptide of the peptide moiety of peptidogly-
can (104). The active site of PBPs is rapidly acylated by the
-lactam, but the deacylation step is so slow that the proteins
are terminally inactivated (37). Autolytic enzymes then trigger
cell death under the influence of -lactams (105). In Staphy-
lococcus aureus, cell death occurs due to puncturing of the cell
wall by the autolytic enzymes of the so-called splitting system
(101), as the initiation of a new septum is inhibited, but the cell
division cycle continues as scheduled. Bacteriolysis subse-
quently occurs when the cells are already dead (38).
PBPs belong to the protein superfamily of penicilloyl serine
transferases, which also includes -lactamases and -lactam
receptors such as BlaR1. All members of this protein family
contain three common, conserved motifs, SXXK, (S/Y)X(N/
C), and (K/H)(T/S)G, which together form the active site.
Although the primary sequence can be highly divergent, -lac-
tam receptors and serine -lactamases are considered to have
evolved from PBPs, with -lactamases having acquired the
ability to rapidly hydrolyze the penicilloyl-enzyme intermedi-
ate, resulting in destruction of the -lactam (37).
LOW-AFFINITY PENICILLIN-BINDING PROTEINS
MEDIATING -LACTAM RESISTANCE
Staphylococci. Methicillin-resistant S. aureus (MRSA) iso-
lates appeared shortly after the introduction of methicillin, the
first penicillinase-resistant -lactam to come into clinical use,
which was in 1960 (5). Methicillin resistance is due to the
acquisition of SCCmec (staphylococcal cassette chromosome
mec [51], formerly termed the mec determinant). SCCmec is
considered a novel type of mobile element that has been
termed a “resistance island,” in analogy to pathogenicity is-
lands (54, 58). SCCmec is thought to be of nonstaphylococcal
origin, as it differs from the rest of the staphylococcal chromo-
some in its GC content. However, its reservoir has not been
clearly identified. Several SCCmec subtypes have been charac-
terized (4, 51, 63) that differ in their sizes, genes, and the
additional resistance determinants that they contain, as well as
in their clonal distributions. The gene responsible for methi-
cillin resistance, mecA, encodes an additional PBP, PBP2
(synonym PBP2a), that has a lower affinity to methicillin and
other -lactam derivatives.
One of the characteristic features of methicillin resistance is
its heterogeneity; in a given population of S. aureus, the ma-
jority of cells are often resistant to a relatively low concentra-
tion of methicillin, while a small proportion (108 to 102 of
the cells) are able to grow at higher concentrations. This het-
erogeneity is the reason for the failure of -lactam therapy in
MRSA infections. It has been demonstrated that the level of re-
sistance does not necessarily correlate with the amount of PBP2
expressed (86), but there is no satisfactory genetic or biochem-
ical explanation for this phenomenon, although many muta-
tions leading from high-level resistance to heteroresistance in
vitro have been identified (for a review, see reference 11).
In the absence of the mecA gene, staphylococci may acquire
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-lactam resistance via mutations that lead to overexpression
of endogenous PBP2 and/or PBP4 or mutations that reduce
their penicillin affinities (43, 50). Clinical S. aureus isolates with
such mutations have been identified and have been termed
MODSA in reference to their modified PBPs (106). Further-
more, a decreased affinity of PBP3 for -lactams was found to
lead to low-level methicillin resistance in Staphylococcus epi-
dermidis (78). Overexpression of a penicillinase in a specific
genetic background, in the so-called borderline resistant S.
aureus (BORSA), may also lead to low-level methicillin resis-
tance (6). These two types of resistance mechanisms have less
clinical impact than true methicillin resistance in S. aureus and
were never observed to achieve more than borderline resis-
tance in clinical isolates.
Pneumococci. In Streptococcus pneumoniae, target alteration
is the main mechanism of resistance to penicillin. In contrast to
methicillin resistance in staphylococci, penicillin resistance
arises by modification of endogenous PBPs. The first PBPs to
be affected are PBP2b or the essential PBP, PBP2x, depending
on the antibiotic used for selection (41, 59). Mutations in just
three amino acids in the active-site region of PBP2x are suffi-
cient to create low-affinity derivatives (55). Additional gene
diversity is created by horizontal exchange of DNA fragments
between strains or even with commensal streptococci, resulting
in highly mosaic genes. Some very low affinity PBP2x variants
from clinical isolates contain more than 100 amino acid sub-
stitutions spread over the entire sequence (47, 61, 83). Muta-
tions in PBP2x and PBP2b are sufficient for midlevel resis-
tance, but to achieve high-level penicillin resistance, all six
endogenous PBPs can be modified. The combination of several
highly resistant PBPs may raise the penicillin MIC 100- to
1,000-fold (45, 114). Similar to staphylococci, it was found that
additional genes other than pbp genes are involved in pneu-
mococcal -lactam resistance, as transformation of susceptible
strains with only the pbp genes from highly resistant strains was
not sufficient to achieve the same level of resistance (46, 96).
Enterococci. Enterococci are naturally less susceptible to
-lactams than pneumococci or staphylococci (35). Their in-
trinsic -lactam resistance is due to endogenous low-affinity
PBP5, which is not essential (91). Acquired resistance to higher
antibiotic concentrations is associated with the overproduction
of PBP5 and/or a decreased affinity of PBP5 for the -lactam
(34). However, the role of PBP5 in high-level resistance is
likely to depend on additional factors. The expression of pbp5
FIG. 1. Pathway and inhibitors of peptidoglycan synthesis in S. aureus (adapted in part from references 17 and 111). (I) The assembly of the
lipid II precursor is universal for eubacteria; the MurA reaction is the first step committed to peptidoglycan synthesis (17, 111). (II) The
interpeptide is synthesized on the membrane-bound precursor. (III and IV) Extracellular steps catalyzed by transglycosylases and transpeptidases
(PBPs) lead to mature peptidoglycan.
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alleles from highly resistant strains in a penicillin-susceptible
pbp5 deletion mutant of Enterococcus faecium conferred only
moderate, not high-level, resistance (91). As the sensitive PBPs
are inactivated by -lactams, PBP5 is able to synthesize muro-
peptide dimers and trimers in abundance, but higher oligomers
are reduced (92). Inactivation of PBP5 of Enterococcus faecalis
leads to hypersusceptibility to all -lactams (93). Interestingly,
the first low-affinity PBP found to be located on a plasmid is
PBP3r from Enterococcus hirae, which is almost identical to
PBP5 (80, 82).
STRUCTURAL CHARACTERISTICS OF NORMAL
AND LOW-AFFINITY PBPS
Depending on the species, bacteria contain between four
and eight PBPs, which are divided into several classes (39).
Monofunctional PBPs contain a penicillin-binding (PB) do-
main and largely perform accessory functions in peptidoglycan
synthesis. Class A multimodular, bifunctional PBPs contain a
non-PB (n-PB) module that has transglycosylase activity, which
has been demonstrated for PBP1a and PBP1b in Escherichia
coli (71) and PBP2 in S. aureus (79). The PB domains of class
A PBPs perform the transpeptidase function. Class A PBPs
can therefore perform all necessary functions in peptidoglycan
cross-linking.
Class B multimodular PBPs contain an n-PB domain which
does not appear to have transglycosylase activity and a PB
domain which has transpeptidase activity. The exact function
of the n-PB module is unknown, but it may mediate interaction
with other proteins of the cell wall synthesis machinery (53)
and it is essential for folding (39). The low-affinity PBPs of
enterococci and staphylococci are closely related and form
PBP subclass B1, which stands apart from the unmodified class
B PBPs and also from S. pneumoniae PBP2x (39). As an ex-
ception, Bacillus subtilis PBP3 groups in the B1 cluster but has
not been linked to any low-affinity property (70). Class B PBPs
must cooperate with either a monofunctional transglycosylase
or the transglycosylase domain of a class A PBP to synthesize
cross-linked peptidoglycan. In S. aureus, this assumption was
recently supported by the observation that PBP2 needs the
intact transglycosylase module of the resident PBP2 in order to
confer methicillin resistance (79). However, there are indica-
tions that PBP2 is a very poor transpeptidase that only barely
TABLE 1. All species of grampositive bacteria found to have a FemABX homolog also bear an interpeptide in their peptidoglycan
Species Interpeptide Peptidyl transferase (FemABX homolog), accession no. Reference(s)
Staphylococcus aureus Gly5 FemA, P14304; FemB, P14305; FmhB, AAD23961; FmhA,
AAD23960; FmhC, AAD23963
10, 49, 84, 88, 109
Staphylococcus epidermidis Gly2-3–L-Ser1-2, L-Ala–Gly4 FemA, JC5325; FemB, JC5326 1, 52, 88
Staphylococcus spp. Gly5, Gly2-3–L-Ser1-2, L-Ala–Gly4 S. anaerobius FemA, AAD33940; S. capitis FemA, AAC69633;
S. cohnii FemA, AAD45259; S. gallinarum FemA, AAD45258;
S. haemolyticus FemA, AAC69631; S. hominis FemA,
CAA73372; S. intermedius FemA, AAD33941; S. lugdunensis
FemA, AAC69632; S. saprophyticus FemA, CAA73373; S. schlei-
feri FemA, AAC69636; S. sciuri FemA, AAC69635; S. xylosus
FemA, AAC69634; S. warneri FemA, AAD33942; S. haemolyti-
cus FemB, AAD22133; S. simulans Lif, AAB53784; S. capitis
Epr, BAA21486; S. sciuri Epr, AAG16879;
Streptococcus pneumoniae L-Ala–L-Ser, L-Ala2 FibA, CAB89120; FibB, CAB89121; MurMN, AJ250764 33, 88, 114
Streptococcus mutans L-Thr–L-Ala 88
Streptococcus pyogenes L-Ala2-3 88
Streptococcus thermophilus L-Ala2-3 AAK18829 88
Streptococcus zooepidemicus L-Ala2-3 Zif, AAC46073 7, 88
Streptococcus equi L-Ala2-3
Streptococcus milleri L-Thr–Gly MilF, AF243359 13, 88
Enterococcus faecalis L-Ala2-3 16, 88
Clostridium perfringens Gly BAB81796 88
Streptomyces spp. Gly S. coelicolor, CAB45460; S. toyocaensis StaO, AAM80555 81, 88
Weissella viridescens (Lacto-
bacillus viridescens)
L-Ala–L-Ser AAG21689 48, 88
Deinococcus radiodurans Gly2 AAF10635 88
Treponema pallidum Gly AAC65773 110
Borrelia spp. Gly AAB91521 115
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allows the cells to survive the action of methicillin. When
highly methicillin resistant S. aureus strain COL is grown in the
presence of methicillin concentrations sufficient to inactivate
the endogenous PBPs, PBP2 forms a poorly cross-linked cell
wall containing mainly un-cross-linked muropeptides and only
a few muropeptide dimers or trimers. The same strain grown in
antibiotic-free medium produces highly cross-linked pepti-
doglycan (25).
Little is known about the structural changes that give rise to
low-affinity PBPs. The recent determination of the structure of
E. faecium PBP5fm, which belongs to the B1 group of PBPs,
has provided some evidence into the mechanism that makes
these proteins resistant to -lactams. The active site of PBP5fm is
surrounded by a number of amino acids that are strongly con-
served in class B1 PBPs but not in PBPs of other classes and
that may confer greater rigidity and a reduced affinity of -lac-
tams for the active site of this group of proteins (87).
In PBP2x from highly resistant strain SP328 (27), the helix
that harbors the SXN motif is highly flexible, causing the serine
to point away from the active site and leading to a decreased
affinity for the antibiotic. Important amino acid exchanges are
T338A in the STMK motif, which leads to a reduced rate of
acylation by the -lactam (27, 69). In a variant of PBP2x that
has a higher affinity for penicillin (40), the active site lies in a
deep groove of the protein. In contrast, the flexible architec-
ture of PBP2x from resistant strain SP328 results in an “open”
active-site pocket that may be able to accommodate branched
peptidoglycan precursors (27), for which it apparently exhibits
a substrate preference, as will be discussed below. Although
kinetic studies of low-affinity PBP2x also demonstrated that it
has a reduced affinity for a structural analog of the linear stem
peptide (69, 117), studies with an analog of the branched stem
peptide have not been done to confirm the substrate prefer-
ence hypothesis.
LOW-AFFNITY PBPS AND VANCOMYCIN RESISTANCE
The recent first report of a vancomycin-resistant S. aureus
isolate that has acquired the vanA gene from enterococci (19)
raises a number of questions: does the incorporation of D-
lactate into the peptidoglycan precursor affect the function of
the cross-linking enzymes, particularly PBP2? If yes, how does
this affect resistance to agents other than vancomycin?
Some indications of the answers to this problem may be
found in studies conducted with enterococci. It appears that
the presence of D-lactate does not affect peptidoglycan cross-
linking under unchallenged growth conditions (15, 21). How-
ever, vancomycin and -lactams have been shown to exhibit a
synergistic action in vancomycin-resistant enterococci, which
indicates that their low-affinity PBPs do not cope well with the
modified stem peptides (2, 42).
In a recent study with S. aureus (23), the addition of D-serine,
D-threonine, and D-phenylalanine to the growth medium re-
duced the levels of cross-linking and methicillin resistance, as
these amino acids were efficiently incorporated in the fifth
position of the peptidoglycan stem peptide. The same effect
has been observed when glycine was added to the growth me-
dium (22). However, these experiments did not include D-
lactate, and the effect on vancomycin resistance was not deter-
mined. Although the most recent of these studies concluded
that vanA-mediated vancomycin resistance and mecA-medi-
ated methicillin resistance may be mutually exclusive, this hy-
pothesis does not hold true for the recently reported vanco-
mycin-resistant S. aureus strain that also carries mecA and for
which the oxacillin MIC is 16 g/ml (19).
BIOSYNTHESIS OF BRANCHED CELL WALL PEPTIDES
AND IMPACT ON -LACTAM RESISTANCE
Cross-linking of peptidoglycan (Fig. 1) by transpeptidases
(PBPs) always occurs via a diamino acid in the stem peptide,
generally meso-diaminopimelic acid, L-Lys, or L-Orn. Cross-
links occur either directly or via an interceding spacer (or
interpeptide), which consists of one to five amino acids and
which branches off the diamino acid. The interpeptide may
contain amino acids in the L or D conformation (88).
In S. aureus, the pentaglycine interpeptide is synthesized in
a sequential fashion on the cytoplasmic face of the membrane,
with lipid II as a substrate (57, 66), where the first glycine is
attached to the ε-amino group of L-lysine (56, 97). The glycine
donor is glycyl-tRNA (65), and a fraction of tRNAs is exclu-
sively used in interpeptide synthesis (18). Although tRNAs
participate in interpeptide formation, the reaction is not inhib-
ited by antibiotics that target protein translation, and thus, it
was concluded that interpeptide synthesis is achieved by a
nonribosomal mechanism (57). In an alternative pathway, in
species such as E. faecium, whose interpeptide contains D-
amino acids, the amino acids are incorporated from phosphate
precursors (17, 88).
FemABX protein family. The branched peptide chain is syn-
thesized by a family of nonribosomal peptidyl transferases
(Fig. 2) that use either the lipid II-linked peptidoglycan pre-
cursor or, alternatively, the soluble, UDP-MurNAc-linked
stem peptide (cf. Fig. 1) as a substrate for the addition of one
or several additional amino acids to the peptidoglycan stem
peptide in a sequential fashion. The impact of these factors on
cell wall composition and, in clinically relevant species, on
antibiotic resistance is outlined below.
Staphylococcus. The cause of heterogeneity in methicillin
resistance was initially investigated by transposon-mediated
mutagenesis (9), which led to the identification of a number of
loci whose inactivation lowered the resistance level, and the
terms fem factors (for factors essential for methicillin resis-
tance) and aux factors (for auxiliary) were coined (8, 12, 26). It
was shown that all fem factors are housekeeping genes, most of
which play a role in cell wall biosynthesis. Mutation of the
femAB operon affects the glycine content in the cell wall (64).
It was determined that FemA specifically adds glycines 2 and 3
of the pentaglycine interpeptide, while FemB, which shares
39% identity and 59% similarity with FemA on the amino acid
level, adds glycines 4 and 5 (28). femAB mutants completely
lose resistance to methicillin and become hypersusceptible to
many unrelated antibiotics (62). femAB mutant cells are pseu-
domulticellular with thickened cell walls and abnormal septa
due to impaired cell wall turnover and are resistant to the
glycyl-glycine endopeptidase lysostaphin (49). It is clear from
these observations that not only low-affinity PBP2 but also the
endogenous PBPs cope very badly with the shortened penta-
glycine interpeptide. FemA and FemB homologs have been
identified in all staphylococcal species tested (1, 112).
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The factor (femX) that catalyzes the incorporation of the
first glycine long remained elusive. Inactivation of femA or
femB yielded viable cells, but it was demonstrated that they had
acquired compensatory mutations in order to survive (62). It
was deduced that the inactivation of femAB would otherwise
be lethal and that the postulated femX was probably essential
(60). The advent of whole-genome sequencing made it possible
to search the complete S. aureus genome for additional ho-
mologs of femAB; and three sequences were identified and
named fmhA, fmhB, and fmhC (for fem homolog) (109). fmhA
and fmhC (alternative name, eprH [99]) were inactivated with-
out a discernible phenotype, while inactivation was impossible
for fmhB, making it a likely femX candidate (109). A promoter
insertion strategy in which cells could be depleted of FmhB was
used to demonstrate its role in the addition of glycine 1 of the
interpeptide chain. FmhB depletion leads to the virtual disap-
pearance of glycine-substituted muropeptide monomers and to
a significant reduction in the degree of peptidoglycan cross-
linking. The introduction of this construct into an MRSA back-
ground causes a complete loss of resistance to methicillin (84).
It can be concluded from these observations that the staphy-
lococcal cell can tolerate, if barely, the reduction of the inter-
peptide to one glycine, but the complete lack of glycine sub-
stitution is lethal. In addition, PBP2, the low-affinity PBP
responsible for methicillin resistance, is unable to perform its
function in the absence of a five-membered interpeptide chain.
Pneumococcus. In S. pneumoniae, the peptide side chain,
consisting of Ala2 or Ser-Ala, is dispensable (90). In an early
study of the pneumococcal cell wall, Garcia-Bustos and To-
masz (36) analyzed a number of penicillin-susceptible and -re-
sistant clinical strains and observed branched as well as un-
branched peptidoglycan stem peptides. While in resistant
strains there was a large amount of Ala2- or Ser-Ala-substi-
tuted peptides, in susceptible strains, the situation was vari-
able: in the clinical strains analyzed, the muropeptides were
predominantly unsubstituted, whereas in laboratory strain R6
there was a significant fraction of branched muropeptides
present. In both the susceptible and the resistant strains ana-
FIG. 2. Dendrogram of the FemABX protein family. Branch lengths are proportional to phylogenetic distances. Experimentally confirmed
family members are shown in boldface type. The number of sequenced FemA homologs of Staphylococcus spp. has become quite large, and they
are shown in an enlarged inset. The GenBank database was searched with the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/) (3) by using
S. aureus FmhB as the query sequence. In the case of Streptococcus equi and Streptococcus pyogenes, three FemABX homologs were found, two
of which are related to FibA/MurM of S. pneumoniae and one of which is related to FibB/MurN of S. pneumoniae. Unfinished microbial genomes
were searched by using the tblastn program (http://www.ncbi.nlm.nih.gov/Microb_blast/unfinishedgenome.html). Preliminary sequence data from
unfinished genomes were obtained from The Institute for Genomic Research website at http://www.tigr.org and from the Sanger Center at http:
//www.sanger.ac.uk. In the case of MurM, where multiple, more than 90% identical alleles are available, one representative sequence (that of strain
R36A) was chosen. Protein sequences were aligned by using the ClustalW program (102), and the dendrogram was constructed by using the
TreeView program (75).
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lyzed, the muropeptide monomer fractions contained a detect-
able amount of nonsubstituted muropeptides; but the dimer,
trimer, and oligomer fractions appeared to contain almost ex-
clusively substituted muropeptides. These findings led to the
conclusion that the PBPs exhibit a substrate preference for sub-
stituted stem peptides; the preference appeared more marked
in resistant strains, which have modified, low-affinity PBPs. In a
penicillin-resistant transformant of strain R6, nonbranched
muropeptide dimers were undetectable, leading Garcia-Bustos
and Tomasz (36) to suggest that PBP2x may discriminate
against unsubstituted stem peptides, a notion that has recently
been supported by its crystal structure (discussed above).
The genes for the alanine and/or serine transferases of S.
pneumoniae have recently been identified by two independent
groups (33, 114) and named murMN and fibAB, respectively.
Inactivation of these genes in penicillin-resistant strains results
in greatly decreased levels of resistance to -lactams (reduc-
tions of more than 32-fold), with a complete breakdown of
resistance to cefoxitin, which predominantly targets PBP2x.
The MIC is reduced twofold for penicillin-sensitive laboratory
strain R6. In addition, the level of total cell wall cross-linking
is reduced (114). As might be expected with such a weakened
cell wall and in analogy to femAB mutants (62), murMN mu-
tants are hypersusceptible to all other classes of cell wall syn-
thesis inhibitors (32). Surprisingly, laboratory strain R36A con-
tains a very small amount of alanine- or serine-substituted
muropeptides compared to the amounts in strain R6, even with
an intact murMN operon (33). The murM and murN genes of
laboratory strains R6 and R36A, which have essentially the
same genetic backgrounds, differ in only two and one amino
acid positions, respectively. It is conceivable that variations in
the transcriptional activity of murMN may cause this significant
difference in their peptidoglycan compositions.
As is the case with many genes in pneumococci (44, 45), the
murMN genes, like PBP2x, exhibit a mosaic structure which
may explain the strain-dependent differences in branched mu-
ropeptide content. The variability of the murMN genes appears
to be responsible for variations in the catalytic efficiencies of
their products (30, 95). Again, in resistant strains, a larger
amount of branched muropeptides indicates that these strains
contain murM alleles that encode a highly efficient enzyme.
The presence of a high-efficiency murM allele appears to be a
prerequisite for the acquisition of high-level resistance to pen-
icillin by remodeled, low-affinity PBPs, as only transformation
by both the low-affinity PBPs and the murMN genes from a
resistant donor strain results in high-level resistance in a sus-
ceptible recipient (95).
The correlation between branched peptidoglycan and low-
affinity PBPs as the sole resistance mechanisms may be ques-
tionable due to a report that dissociated penicillin resistance
from branched peptidoglycan peptides by transformation (89).
When a susceptible, directly cross-linked strain was trans-
formed with DNA from a resistant donor with low-affinity
PBPs and a branched-chain peptidoglycan, the first round of
transformation resulted in resistant strains that had acquired
both the branched peptides and the low-affinity PBPs of the
donor. However, in a second round of transformation, resis-
tance was no longer coupled to the branched-chain peptidogly-
can, as the strains were resistant to penicillin but had retained
the recipient’s peptidoglycan structure. Examination of the
PBP profiles indicated that most of these second-round trans-
formants had acquired changes, possibly point mutations, lead-
ing to PBPs with reduced -lactam affinities. Conceivably, mu-
tations in genes other than murMN or pbp were selected in
these experiments; therefore, the study does not necessarily
invalidate the link between resistance and peptidoglycan struc-
ture.
The description of MurMN in S. pneumoniae has given valu-
able insights into the specificity of the FemABX family of
peptidyl transferases. Filipe et al. (31) have analyzed a set of
murM alleles and pinpointed the region that determines which
amino acid is incorporated into the peptidoglycan precursor.
The exchange of codons 244 to 274 between murM alleles from
two strains incorporating mainly seryl-alanine (strain KY17) or
dialanine (strain DE1) determined the ratio of serine versus
alanine that was incorporated. In particular, the amino acid in
position 260 was determined as the major difference in these
two strains. A single amino acid exchange (T260K) in murM of
strain KY17, indeed, slightly increased the alanine content of
the peptide side chain, but other residues in the region from
codons 244 to 274 must be assumed to affect the specificity of
murM as well. A Q27E/T mutation had no measurable effect,
although it was suggested that this amino acid position may be
involved in catalysis in FemX of Weissella viridescens (see be-
low) (48). In addition, the deletion of as few as 50 amino acids
at the N terminus or 10 amino acids at the C terminus inacti-
vated MurM. This effect was also observed in the case of FemA
and FemB of S. aureus, in which point mutations at the C
terminus, which lead to a stop codon, completely inactivated
the proteins (60).
Lactobacillus. Hegde and Shrader (48) have recently identi-
fied FemX in W. viridescens (formerly Lactobacillus viridescens)
and were able to reconstitute the addition of glycine to the
soluble, UDP-linked peptidoglycan precursor from glycyl-
tRNA in vitro. Their attempt to reconstitute the same reaction
with S. aureus FmhB was unsuccessful, probably because this
reaction occurs on lipid II, whereas in W. viridescens it occurs
on the soluble precursor (cf. Fig. 1).
Enterococcus. The catalytic activities of the FemABX ho-
mologs in E. faecalis have been analyzed (16). Two homolo-
gous open reading frames were found. Both orf1 (coding for a
protein of 48.3 kDa) and orf2 (coding for a protein of 46 kDa)
were recombinantly expressed and reconstituted in an in vitro
assay. Only the product of orf2 has UDP-MurNAc-pentapep-
tide:L-alanine ligase activity and therefore corresponds to S.
pneumoniae MurM, to which it is closely related (Fig. 2). It is
conceivable that a coupled reaction with Orf1 and Orf2 would
demonstrate the activity of Orf1, which groups with MurN in
Fig. 2. The effect of mutations of orf1 and orf2 on -lactam
resistance has not yet been determined.
Endopeptidase resistance factors. The family of FemABX-
like proteins also includes immunity factors that protect pro-
ducers of interpeptide-specific endopeptidases against their
own products by substituting some of the amino acid positions
in their interpeptides. epr (endopeptidase resistance) from
Staphylococcus capitis (100) and lif (lysostaphin immunity fac-
tor) from Staphylococcus simulans bv. staphylolyticus (20, 103)
incorporate serine into the interpeptide at specific positions
and thereby make the cell wall resistant to glycyl-glycine en-
dopeptidases such as lysostaphin (29, 108). Interestingly, the
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incorporation of serine into the peptide side chain due to
expression of epr in an MRSA background does not appear to
affect methicillin resistance (100). This finding indicates that
although PBP2 is dependent on a five-membered interpeptide
bridge, it does not appear to discriminate between interpep-
tides consisting of glycine only or glycine and serine. Interest-
ingly, the two additional FemABX homologs in S. aureus,
FmhA and FmhC/EprH, are most closely related to Lif and
Epr (Fig. 2). As mutation of these genes did not appear to
cause a phenotype (99, 109), fmhA and fmhC may be silent or
almost inactive remnants of genes encoding serine-incorporat-
ing enzymes in S. aureus. They may even be responsible for the
somewhat elevated level of serine incorporation that was ob-
served in a partial femAB mutant (24).
In Streptococcus milleri, the endopeptidase millericin B (milB)
is coorganized with the immunity factor milF. MilF substitutes
leucine in the interpeptide for the endogenous threonine (13).
In Streptococcus zooepidemicus, zoocin (zooA) and its corre-
sponding immunity factor, zif, have been described (94). How-
ever, it is unclear whether Zif substitutes any amino acids in
the interpeptide (7).
ROLE OF BRANCHED-CHAIN PEPTIDES
IN CELL DIVISION
In addition to their impact on -lactam resistance, branched
cell wall peptides play an important role in cell division. femAB
mutants, which have a shortened interpeptide, exhibit thick-
ened septa and are pseudomulticellular due to impaired cell
separation (49). It has been shown that endogenous glycyl-
glycine endopeptidases are involved in cell separation, and
femAB mutants are largely resistant to the actions of such
endopeptidases (98), which explains this defect in cell division.
On the other hand, the major autolysin Atl, which is implicated
in lytic death in the presence of penicillin (described above), is
not impaired by the shortened interpeptide, as its mature do-
mains have endo--N-acetylglucosaminidase and N-acetylmu-
ramyl-L-alanine amidase activities (101), and is not affected by
the interpeptide structure.
ANCHORING OF CELL SURFACE PROTEINS
In addition to their influence on resistance to -lactams
and their crucial role in cell wall integrity and cell division,
branched-chain muropeptides also play a role in virulence. In
S. aureus, important virulence factors are covalently attached
to the cell wall interpeptide. Examples are protein A, fibrino-
gen-binding protein (clumping factor), and other so-called
MSCRAMMs (microbial surface components recognizing ad-
hesive matrix molecules) that enable adhesion to host tissues
(73, 76). Branched side chains that do not participate in pep-
tidoglycan cross-linking serve as anchoring points for such cell
wall-linked proteins. Cell wall-localized proteins carry a char-
acteristic C-terminal sorting signal with a conserved LPXTG
sequence (72) that is recognized in S. aureus by the enzyme
sortase (SrtA) (67). This enzyme tethers the proteins to the
interpeptide in a transpeptidase reaction, which occurs on lipid
II on the extracellular face of the membrane (77, 85). It has
been shown that SrtA will not accept linear stem peptides
lacking glycine as a substrate (85) and that with the shortened
interpeptides containing only one and three glycines in femAB
and femB mutants, respectively, sorting of cell wall proteins is
impaired (107). In sortase mutants (67, 68), virulence is re-
duced due to an impairment of the anchoring of cell surface
proteins. In analogy, in femAB mutant strains, the truncated
muropeptide side chains are expected to cause a reduction in
virulence due to the concurrent inhibition of the sorting reac-
tion.
A second sortase, SrtB, was found to specifically link IsdC
(encoded by the iron-responsive surface determinant locus of
S. aureus) to the cell wall via an NPQTN sequence (68).
It may be assumed that in other species as well a sortase
catalyzes attachment of proteins to the cell wall via the
branched peptides. In S. pneumoniae, neuraminidase contains
a sorting signal, and several cell wall-localized proteins in en-
terococci also contain this signature sequence (73). A sortase
has indeed been described recently in Listeria monocytogenes,
whose cell wall peptides are directly cross-linked via meso-
diaminopimelic acid (14), indicating that the substrate require-
ments for each sortase correspond to the species’ peptidogly-
can structure.
CONCLUSION
The FemABX protein family has emerged as a broadly dis-
tributed group of peptidoglycan stem peptide peptidyl trans-
ferases. The interpeptide serves as a means for cross-linking of
the cell wall, mediated by the PBPs. Some PBPs appear to
exhibit a marked substrate preference for the peptide side
chain, as may be the case with PBP2x in S. pneumoniae. In
S. aureus, the PBPs are unable to function at all if the inter-
peptide is lost. The reduction in length or the absence of the
interpeptide impairs the structure of the cell wall and renders
-lactam-resistant strains that rely on low-affinity PBPs suscep-
tible to the antibiotics. A subgroup of FemABX family mem-
bers serve as immunity factors in producers of interpeptide-
specific endopeptidases. In addition, the interpeptide plays an
important role in cell separation and virulence.
A database search for FmhB homologs yields related se-
quences in a wide range of bacterial genomes. Species as di-
verse as Borrelia burgdorferi, Streptomyces coelicolor, and Clos-
tridium perfringens contain a FemABX homolog (Table 1; Fig.
2). It is not surprising that all species containing a FemABX
homolog also bear a peptide side chain in their peptidoglycan
(Table 1), which makes it likely that all homologs encode
functional FemABX family proteins. However, the function of
these FemABX homologs needs to be confirmed experimen-
tally. Interestingly, in bacteria such as Lactococcus lactis or
E. faecium, which contain D-amino acids in their interpeptides,
no FemABX homolog can be found. These amino acids are
presumed to be attached by an entirely different but not yet
identified mechanism (17, 88).
It appears that the reduction of -lactam affinity has in-
curred structural restraints on the remodeled PBPs of S. aureus
and S. pneumoniae. Their modified active site may exhibit a
substrate preference for peptidoglycan precursors with a
branched peptide chain. Unfortunately, as only the structures
of S. pneumoniae PBP2x and E. faecium PBP5fm have been
solved, this remains speculation. The precise requirements for
branched peptide peptidoglycan precursors for the resistance
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level achieved in pneumococci, mediated by low-affinity PBPs
with various levels of modification, will need to be carefully
analyzed in an isogenic system. In addition, the importance
of the branched peptide structure for -lactam resistance in
E. faecalis remains to be demonstrated.
The observation that S. aureus PBP2 and E. faecium PBP5
are poor transpeptidases if the sensitive PBPs are masked
by -lactams (25, 92) indicates that these “rescue transpep-
tidases” (87) have reduced their affinities to -lactams at the
cost of efficiency. If the activities of these PBPs are further
impaired by a suboptimal substrate, they are simply unable to
perform their functions under antibiotic pressure, as is shown
by the fem-type mutations in S. aureus and S. pneumoniae and
the synergism between vancomycin and -lactams in vancomy-
cin-resistant enterococci.
The global spread of antimicrobial resistance has created a
need for new agents for the treatment of bacterial infections.
The knowledge that has been gained about the FemABX fam-
ily of proteins suggests that they are a suitable target for the
development of new antimicrobials. If an inhibitor of FemABX
proteins was developed, it would be a potent and highly spe-
cific antimicrobial agent in those organisms in which the inter-
peptide structure is essential (60). Alternatively, in organisms
in which the peptidoglycan interpeptide is dispensable, such as
penicillin-resistant pneumococci, a FemABX inhibitor would
certainly restore the activities of -lactams. As a supporting
strategy, the virulence of epidemic strains could be reduced
(74) by preventing the attachment of cell wall-linked proteins
via inhibition of the FemABX homologs and subsequent im-
pairment of sorting of these virulence factors. In addition,
peptidoglycan itself has been identified as a virulence factor
eliciting host responses (113, 116). In analogy to mutation of
femAB (64), it is conceivable that inhibition of FemABX fac-
tors might lead to a reduction in cell wall turnover or pepti-
doglycan “shedding” and thus reduce virulence. In the near
future, as broad-spectrum antimicrobials become increasingly
unreliable, the use of a FemABX inhibitor might be an option
to be explored.
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ADDENDUM IN PROOF
Recent publications of two important crystal structures pro-
vide a basis for further research: D. Lim and N. C. Strynadka,
Nat. Struct. Biol. 9:870–876, 2002; T. Benson et al., Structure
(Cambridge) 10:1107–1115, 2002.
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